Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells

Therapeutic Drug Monitoring

Volumn 31, Issue 3, 2009, Pages 351-359

  Glander, Petra ^a   Sombogaard, Ferdi ^b   Budde, Klemens ^a   Gelder, Teun Van ^b   Hambach, Pia ^a   Liefeldt, Lutz ^a   Lorkowski, Christine ^a   Mai, Marco ^a   Neumayer, Hans H ^a   Vulto, Arnold G ^b   Mathot, Ron A ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Activity assay; IMP dehydrogenase; Kidney transplantation; Mycophenolate mofetil; Pharmacodynamics

Indexed keywords

ADENOSINE PHOSPHATE; CALCINEURIN INHIBITOR; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN; UNCLASSIFIED DRUG; XANTHOSINE PHOSPHATE;

ACCURACY; ARTICLE; BLOOD LEVEL; CELL COUNT; CELL ISOLATION; CELL LYSATE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MONITORING; ENZYME ACTIVITY; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; RELIABILITY; REPRODUCIBILITY; STATISTICAL ANALYSIS;

CELL SEPARATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MYCOPHENOLIC ACID;

EID: 67651121811     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31819c3f3d     Document Type: Article

References (22)

1. Wang W, Hedstrom L. Kinetic mechanism of human inosine 5′- monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry. 1997;36:8479-8483.
2. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation. 1992;53:428-432.
3. Klupp J, Holt DW, van Gelder T. How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol. 2002;9:211-214.
4. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
5. van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant. 2005;5:199-200.
6. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503.
7. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80:S244-S253.
8. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045-2051.
9. Weimert NA, Derotte M, Alloway RR, et al. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit. 2007;29:141-149.
10. Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol. 2004;67:767-776.
11. Sanquer S, Breil M, Baron C, et al. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther. 1999;65:640-648.
12. Vannozzi F, Filipponi F, Di PA, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004;36:2787-2790.
13. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination of inosine 5′-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem. 2001;34:543-549.
14. Glander P, Hambach P, Braun KP, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther. 2003;41:470-476.
15. Braun KP, Glander P, Hambach P, et al. Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. Transplant Proc. 2002;34:1745-1747.
16. Budde K, Glander P, Kramer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation. 2007;83:417-424.
17. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant. 2007;7:888-898.
18. Czock D, Rasche FM, Carius A, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. J Clin Pharmacol 2007;47:850-859.
19. NCCLS Tentative Guideline EP5-T. User Evaluation of Precision Performance of Clinical Chemistry Devices. Wayne, PA: National Committee for Clinical Laboratory Standards; 1984.
20. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
21. van Rossum HH, Romijn FP, Sellar KJ, et al. Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies. Clin Chem. 2008;54:517-524.
22. Albrecht W, Storck M, Pfetsch E, et al. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit. 2000;22: 283-294.